Investor Presentaiton

BION-206 is a first-in-class immuno-oncology agent targeting the CD28/B7 axis Protection of CD28 shedding by BION-206 CD80 CD28 BION-206 CD86 APC T cell MMPs BIOND BIOLOGICS Activated T cells Lowers soluble CD28 levels thus preventing its immunosuppressive effect Restores CD28 signaling in T cells Enables efficient stimulation of T cells in lymph nodes and the TME Enhances the effect of PD1 blockade Biond Biologics Corporate Presentation | May 2021 | Non-confidential 涯 21 24

View entire presentation